Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Cleared to Begin Phase IIa Trial of HBV Drug

Premium

Arrowhead Research this week announced that it has received clearance from regulators in Hong Kong to begin a phase IIa trial of its siRNA-based hepatitis B treatment ARC-520.

The single-dose, dose-escalation trial is designed to determine the drug's ability to suppress hepatitis B surface antigen in combination with the oral antiviral agent entecavir in chronic HBV patients.

Single doses of ARC-520 will be evaluated at up to two ascending doses of 1.0 mg/kg and 2.0 mg/kg, Arrowhead said. At each of the two dose levels to be evaluated, a cohort of 8 patients will be enrolled with 6 being dosed with ARC-520 and 2 being dosed with placebo.

With the regulatory approval in hand, Arrowhead said it expects to begin dosing patients "shortly," and that top-line results from the study will be available in the third quarter of the year.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.